For Research Use Only. Not for Human Consumption.
Recorded market$78.32Recorded exact-size market estimate: 78.32 USD for one 60 mg container (1.305368 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$78.00Member price$59.9023.5% lessMembers save $18.42 on this item vs. recorded market
Neuropeptide preparation for neuroscience research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 60 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$0.9983/mg23.5% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:31 UTC. 1 x 60 mg = 60 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Peptide Labs Oct 10, 2026 UTC | One 60 mg container; 68.99 USD | $1.15/mg | powder; in_stock Selected60mg,1Pack1vial,total68.99USDlyophilizedpowder;publicsale(list89.99),quantitydiscountsexcluded. Price observation; no COA authentication is implied by inclusion. |
| AMC Essentials Oct 10, 2026 UTC | One 60 mg container; 49.99 USD | $0.8332/mg | powder; in_stock Explicitsealedsterileviallyophilizedpowderlabel60mgqty1tier49.99USDJSONLD. Reference10mLliquidcomparisonnotusedforscaling.Ageoverlayunanswered. Price observation; no COA authentication is implied by inclusion. |
| Pure Lab Peptides Oct 10, 2026 UTC | One 60 mg container; 49.99 USD | $0.8332/mg | lyophilized powder; coming soon / unavailable Public USD price for 1 × 3mL vial containing 60mg. Visible Coming Soon conflicts with JSON-LD inStock; treated unavailable. Price observation; no COA authentication is implied by inclusion. |
| Nationwide Peptides Oct 11, 2026 UTC | One 60 mg container; 99.00 USD | $1.65/mg | lyophilized powder; in stock Open selected60mg retailvial USD99 qty1; publisher ProductVariant offer cerebrolysin-60mg explicitlyUSD99. FAQ expanded expresslysuppliedlyophilizedpowder. Noentryaccount/professionalgate afterstableload; no kit/minimum listed. FALL2026 couponexcluded. Replaces Modified Aminos. Price observation; no COA authentication is implied by inclusion. |
| Peptiqo Oct 10, 2026 UTC | One 60 mg container; 50.00 USD | $0.8333/mg | lyophilized powder; in stock Public currentprice50USD; productoverviewsealed vial60mg lyophilized. Price observation; no COA authentication is implied by inclusion. |
| Peptide Lab Australia Oct 11, 2026 UTC | One 60 mg container; 190.00 AUD | $2.21/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Jonezie Labs Oct 10, 2026 UTC | One 60 mg container; 37.00 USD | $0.6167/mg | lyophilized powder; in stock / order request invoice Selected Single Vial60mg total37USD JSON-LD, invoice afterorderreview; couponexcluded. Price observation; no COA authentication is implied by inclusion. |
| Lumo Peptides Oct 11, 2026 UTC | One 60 mg container; 79.95 EUR | $1.49/mg | lyophilized powder; out_of_stock Exact specifications explicitly state 60 mg freeze-dried powder per vial; one vial per pack. EUR79.95 includes VAT; out-of-stock public price observation. Age/country/basic research-only notice has no professional attestation, Terms or liability acceptance requirement; retained read-only under allowed notice exception, no Enter clicked. Price observation; no COA authentication is implied by inclusion. |
| Crystal Peptides Oct 11, 2026 UTC | One 60 mg container; 49.99 EUR | $0.9336/mg | lyophilized powder; in_stock Selected retail product explicitly60mg lyophilized powder, not reconstituted; qty1 singlevial photo/individual unit. EUR49.99 public base, bulk tiers ignored. Publisher separates own nominal powder from branded liquid comparator; own composition/source unconfirmed, price comparison only not pharmaceutical equivalence. No stable entry gate. Price observation; no COA authentication is implied by inclusion. |
| Minuteman Peptides Oct 11, 2026 UTC | One 60 mg container; 150.00 USD | $2.50/mg | lyophilized powder; Out of stock Main listing Cerebrolysin60mg; buy1 SINGLE USD150, lyophilized and vacuum-sealed. Legacy URL slug cortagen20mg contradicts name, but current heading/SKU/offer and Google describe60mg. Legal notice not accepted; no discount signup. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Cerebrolysin – 60 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/cerebrolysin-60-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/cerebrolysin-60-mg/
A low-molecular-weight neuropeptide preparation used in laboratory neuroscience research on neuroprotection and neural plasticity.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain. Clinical research includes stroke rehabilitation, but results depend on the study and outcome. This evidence does not establish a general memory or focus enhancer for healthy people.
Cerebrolysin is not a single peptide with one sequence or molecular mass. Its mixture identity and manufacturing specifications are important to any comparison.
Cortexin and other brain-derived mixtures are separate preparations. A review that includes more than one mixture must identify which product contributed to each result.
One randomized rehabilitation trial reported improved arm-function outcomes, whereas another found no significant overall motor-function difference and a favorable result in a severe-impairment subgroup. A broader Cochrane assessment of acute stroke found no mortality benefit and identified a potential increase in nonfatal serious adverse events.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
Exploratory randomized double-blind CARS trial after stroke, with standardized rehabilitation Reading scope: PubMed abstract and bibliographic record; not full-text review |
Cerebrolysin was associated with better day-90 arm-function and global-status measures than placebo. | The authors called for confirmation in a larger trial. Findings concern rehabilitation after stroke, not cognition in healthy adults. |
| Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke.
Randomized placebo-controlled trial in 70 stroke patients receiving rehabilitation Reading scope: PubMed abstract and bibliographic record; not full-text review |
There was no significant overall motor-function difference between groups; patients with severe impairment showed a favorable subgroup result. | A subgroup benefit does not make the overall comparison positive or establish benefit for all stroke patients. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Both improvement from baseline and improvement beyond rehabilitation plus placebo can occur in the same study. Only the latter addresses the added value of the intervention.
The 2023 Cochrane review evaluated acute stroke trials with defined timing criteria. It found little or no difference in death and a potential increase in nonfatal serious adverse events. That synthesis is separate from a single positive rehabilitation endpoint; the different questions should remain visible.
A favorable tolerability description in one small trial does not erase a safety signal from a wider evidence synthesis.
The reviewed findings do not establish the risk of prolonged use for healthy-person cognitive enhancement or the equivalence of another porcine-derived product.
Clinical exposures are described as a volume of a specified manufactured preparation. They cannot be converted directly into a milligram amount of an unknown peptide blend.
The timing after stroke and the accompanying rehabilitation were part of the interventions. Omitting those details makes a study course look more transferable than it is.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Check the exact preparation, composition standard, manufacturer identification and formulation rather than treating the name as a single pure peptide.
A percentage purity result for one component cannot authenticate the entire mixture or establish equivalence to the clinical material.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. The selected trials differ: one was positive on its main arm-function outcome, while another had a null overall comparison with a favorable severe-impairment subgroup.
No. A damaged nervous system receiving structured rehabilitation is a different population and setting from a healthy person seeking better concentration.
This companion to the Cerebrolysin research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Clinical exposures are described as a volume of a specified manufactured preparation. They cannot be converted directly into a milligram amount of an unknown peptide blend.
The timing after stroke and the accompanying rehabilitation were part of the interventions. Omitting those details makes a study course look more transferable than it is.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.